A major problem in the management of patients with common solid tumours is the detection and treatment of metastatic disease. Accurate staging is important in selecting the best therapy for an individual patient. Recent developments such as CT scanning and ultrasound imaging have improved the accuracy of staging. However, a significant proportion of patients with solid tumours have metastatic disease which currently remains undetected at the time of initial therapy (Report of Advisory Committee on Cancer Registration, 1980) . A possible tool for the detection and localisation of metastatic disease is a suitably labelled tumourspecific antibody, and already the use of radiolabelled conventional antisera has had some success (Mach et al., 1980; Dykes et al., 1980; Goldenberg et al., 1980) . Antisera with the specificity required to discriminate between normal and malignant tissue are difficult to produce. The monoclonal antibody technology yields unlimited quantities of pure reagents which avoid cross reactions from contaminating antibodies and offer the best hope of providing tumour-specific reagents. There are already many reports of production of monoclonal antibodies to human solid tumours (Lennox & Sikora, 1982) with varying degrees of specificity measured by cross reactions with other tumours and normal tissue. Whether a particular antibody will provide good tumour localisation depends on several factors that can be measured in vitro: the degree of cross reaction with normal tissue; the Ig class of the antibody; its affinity for the target antigen; and the amount of free antigen in the serum potentially blocking its localisation. Since predicting the possible effects in vivo of all these factors is difficult, it is important to assess monoclonal antibodies in carefully chosen clinical situations. Such antibodies have other potential advantages over conventional antisera as well as their reproducible specificity. They can be prepared as pure proteins, and thus the total load of labelled foreign protein given to a patient is low. Comparison can be made of antibodies of similar specificity, but varying in antibody class or affinity. Large batches of antibody can be produced allowing the comparison of each preparation by different investigators. Labelled mouse monoclonal antibodies have been successfully used to localise tumour deposits in immuno-suppressed mice bearing human tumour xeongrafts (Levine et al., 1980; Moshakis et al., 1981) . There are, however, few reports of the use of monoclonal antibodies for localisation of tumours in patients where the problems of cross reaction are completely different (Mach et al., 1981; Epenetos et al., 1982) . In this paper we present the results of immunoscintigraphy using a rat monoclonal antibody prepared against colorectal carcinoma in patients with advanced cancer.
Patients and methods Monoclonal antibodies were prepared by immunisng female DA rats on 3 occasions with a purified membrane preparation obtained from fresh human colorectal carcinoma (Takei & Lennox, unpublished) . A suspension of splenic lymphocytes was mixed with the rat myeloma line Y3.1.2.3.Ag (Galfre et al., 1979) and fused in polyethylene glycol (Hales, 1977) . Hybrids were selected in HAT medium (Miller & Ruddle, 1976) and cloned in agar. Supernatants from cloned hybridoma were screened by a solid phase radioimmunoassay for binding to colon carcinoma membranes. Positive supernatants were subsequently screened by immunoperoxidase and immunofluorescence techniques for binding to a range of normal and malignant tissues (Finan et al., 1982) . One antibody was selected (YPC2/12.1) which showed strong binding to all colorectal carcinomas tested but weak binding to normal colon (Figure 1 Figure 4 shows a chest X-ray and whole body subtraction scan in a 63 y-old patient who had an anterior resection performed for a sigmoid carcinoma 6mo previously. Large lung metastases are evident on the chest X-ray and are cleary shown on the subtraction scan in corresponding positions. A deposit is also seen in the liver which was confirmed by CT scan. Figure 5 shows the antibody and CT scans of a patient with extensive liver involvement by colorectal carcinoma. Figure 6 ). Subsequent conventional investigation (X-rays and CT scans) confirmed the presence of metastases at these sites (Figure 7 ). However the demonstration of unsuspected metastases did not affect the clinical Figure 7 Abdominal CT scan of patient 4 (see Table for 
